Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
8 evidence topics · 6 sources
Neuromuscular junction: reduced acetylcholine receptors and sodium channels
“In addition, there is a reduction in the number of AChRs and voltage-gated sodium channels as the result of complement-related injury to the postsynaptic membrane in MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The resultant inefficient neuromuscular transmission is reflected in decremental response in the amplitude of compound muscle action potential (CMAP) during repetitive nerve stimulation (RNS) and abnormal jitter or blocking in single fiber EMG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AChR antibodies: complement fixation, antigenic modulation, and receptor blockade
“The predominant mechanism is the binding of the antibody and activation of the complement cascade, leading to the formation of the membrane attack complex (MAC), which causes damage of the postsynaptic membrane and destruction of synaptic folds which contain AChRs and associated proteins, including voltage-gated sodium channels” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other mechanisms of pathogenicity include: (1) antigenic modulation by the binding and crosslinking of AChRs, leading to increased endocytosis and degradation [37]; and (2) the impairment of AChR function, either by the blocking of ACh binding to the receptor [38] or the prevention of channel opening” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anti-AChR autoantibodies belong to the IgG1 and IgG3 subclasses, that are the strongest activators of the complement system.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Indeed, pathogenicity of these autoantibodies, but not that of anti-MuSK antibodies that belong to IgG4, is mainly due to complement fixation at the NMJ ultimately leading to postsynaptic membrane destruction and impairment of the neuromuscular transmission” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement: classical pathway initiation at the endplate
“In MG, complement-mediated damage of the NMJ occurs via the classical complement pathway, which starts with C1q binding to the Fc domain of the autoantibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Critical steps of the complement cascade are then the cleavage of C3 into C3a and C3b, and of C5 in C5a and C5b, the latter leading to the formation of the membrane attack complex (MAC, C5bC6C7C8C9 also known as C5b-9) that causes focal lysis of the post-synaptic membrane, disruption of post-junctional folds, and ultimately reduction of functional AChRs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In MG, the classical pathway is involved by the initiation of the antigen/antibody complex being recognized by C1q.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The C1q forms a pentameric complex with the C1r2C1s2 serine protease tetramer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C2 also becomes cleaved by C1s to form the C3 convertase (C4b2a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement: deposition at the endplate in patients
“In muscle biopsies from MG patients, IgG and C3 deposition was localized at identical sites of post-synaptic membrane, and specifically on debris of junctional folds in the synaptic clefts and disintegrating junctional folds” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Deposition of C9, the main component of the final and stable MAC, was also observed at the MG end plate regions, with the most intense depositions associated with the destroyed NMJs, indicating that NMJ loss may be largely due to complement activation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with anti-AChR+ MG have autoantibodies and MACs present at NMJs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Damaged NMJs are associated with more severe disease, fewer AChRs, and MACs in synaptic debris.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Complement: evidence from experimental autoimmune myasthenia gravis
“Mice deficient in C3 and C4 demonstrate reduced clinical scores compared to their wild-type littermates during the course of active EAMG, with C3-knockout mice showing no signs of weakness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Complement-deficient EAMG animals showed a preservation of AChR density at the neuromuscular junction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C5-deficient mice demonstrated reduced incidence of disease compared to the C5-sufficient mice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies in animals lacking specific complement proteins have confirmed that MAC formation is required to induce experimental autoimmune MG (EAMG) and NMJ damage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Complement inhibition in EAMG models can prevent disease induction and reverse its progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Complement: C1s and classical pathway activation in patients
“The C1-inhibitor (C1-INH) regulates the classical pathway and is a promising marker in other autoimmune disorders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Serum and plasma C1s-C1-INH levels were higher in MG patients than in matched healthy controls, supporting early classical pathway activation in most MG patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These findings allow prospective validation studies of activated C1s as a putative treatment target and potential accompanying biomarker in MG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Circulating complement protein profile may be used as a biomarker for evaluating patient-specific complement activation: (i) Romi and colleagues found reduced C3 and C4 serum levels in AChR-MG patients with high autoantibody titers, indicating increased in vivo complement consumption” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement: heterogeneity of complement dependence and response to C5 inhibition
“By means of this system, they observed a subset of AChR-MG patients with high complement activity, who are likely patients in whom complement activation is the major disease mechanism, whereas the remaining patients showed low activity, reflecting possible complement-independent autoantibody-mediated mechanisms of NMJ damage” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To date, all FDA-approved drugs in this category focus on targeting the C5 convertase enzyme.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to note that in MG there is no evidence suggesting a role for C5a in the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There remain upward of thirty percent of patients who do not benefit from complement inhibition, which demonstrates the importance of other mechanisms of autoantibody action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MuSK and LRP4 antibodies: complement-independent mechanisms
“MuSK antibodies belong mainly to the IgG4 subclass.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“They do not fix complement and are not strong activators of cell-mediated cytotoxicity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mechanism by which MuSK antibodies exert their pathogenic effect on the neuromuscular junction is via binding to the Ig-like domain of the protein, preventing its phosphorylation, and subsequently disrupting the Agrin-Lrp4-MuSK-Dok-7 signaling pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The LRP4 antibodies are primarily IgG1 and IgG2 subtypes and follow similar clinical presentation to a mild form of early-onset MG (22), inhibit clustering of AChR, and appear not to strongly activate complement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote